Similar articles

• Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.

  McCluskey A, Sim AT, Sakoff JA. McCluskey A, et al. J Med Chem. 2002 Mar 14;45(6):1151-75. doi: 10.1021/jm010066k. J Med Chem. 2002. PMID: 11881984 Review. No abstract available.
• [Tumor promotion by inhibitors of protein phosphatase 1 and 2A].

  Suganuma M, Fujiki H. Suganuma M, et al. Tanpakushitsu Kakusan Koso. 1998 Jun;43(8 Suppl):1102-10. Tanpakushitsu Kakusan Koso. 1998. PMID: 9655968 Review. Japanese. No abstract available.
• Role of phosphoprotein phosphatases in the corpus luteum: I identification and characterisation of serine/threonine phosphoprotein phosphatases in isolated rat luteal cells.

  Ford SL, Abayasekara DR, Persaud SJ, Jones PM. Ford SL, et al. J Endocrinol. 1996 Aug;150(2):205-11. doi: 10.1677/joe.0.1500205. J Endocrinol. 1996. PMID: 8869587
• Characterization of natural toxins with inhibitory activity against serine/threonine protein phosphatases.

  Honkanen RE, Codispoti BA, Tse K, Boynton AL, Honkanan RE. Honkanen RE, et al. Toxicon. 1994 Mar;32(3):339-50. doi: 10.1016/0041-0101(94)90086-8. Toxicon. 1994. PMID: 8016855
• A model for binding of structurally diverse natural product inhibitors of protein phosphatases PP1 and PP2A.

  Gupta V, Ogawa AK, Du X, Houk KN, Armstrong RW. Gupta V, et al. J Med Chem. 1997 Sep 26;40(20):3199-206. doi: 10.1021/jm960873x. J Med Chem. 1997. PMID: 9379439